Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,499
  • Shares Outstanding, K 70,382
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,340 K
  • EBIT $ -33 M
  • EBITDA $ -23 M
  • 60-Month Beta 2.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.64

Options Overview Details

View History
  • Implied Volatility 343.75% ( +124.67%)
  • Historical Volatility 73.70%
  • IV Percentile 96%
  • IV Rank 43.18%
  • IV High 737.40% on 01/03/24
  • IV Low 44.61% on 05/15/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 6,627
  • Volume Avg (30-Day) 2,757
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 128,575
  • Open Int (30-Day) 120,553

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +399,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7720 +15.03%
on 12/13/24
1.3000 -31.69%
on 11/27/24
-0.3520 (-28.39%)
since 11/20/24
3-Month
0.7720 +15.03%
on 12/13/24
1.3900 -36.12%
on 11/13/24
-0.3220 (-26.61%)
since 09/20/24
52-Week
0.4986 +78.10%
on 01/26/24
1.7200 -48.37%
on 04/23/24
-0.3320 (-27.21%)
since 12/20/23

Most Recent Stories

More News
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SLS : 0.8880 (-1.11%)
SELLAS Life Sciences Reports Promising Data from Phase 2 Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia

SELLAS reports median overall survival over 7.7 months and a 56% overall response rate for AML patients using SLS009.Quiver AI SummarySELLAS Life Sciences Group, Inc. has released promising new data from...

SLS : 0.8880 (-1.11%)
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SLS : 0.8880 (-1.11%)
SELLAS Life Sciences Group Identifies ASXL1 Mutations as Predictive Biomarkers for SLS009 Efficacy in Solid Cancers

SELLAS Life Sciences reports high efficacy of SLS009 in ASXL1 mutated solid cancers, supporting targeted clinical trials.Quiver AI SummarySELLAS Life Sciences Group, Inc. has announced promising preclinical...

SLS : 0.8880 (-1.11%)
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

SLS : 0.8880 (-1.11%)
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SLS : 0.8880 (-1.11%)
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SLS : 0.8880 (-1.11%)
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SLS : 0.8880 (-1.11%)
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

SLS : 0.8880 (-1.11%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.2900 (+15.18%)
BPTH : 1.2600 (-15.44%)
LGVN : 1.6500 (+3.12%)
SLS : 0.8880 (-1.11%)
BMY : 57.33 (+1.83%)

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 0.9813
2nd Resistance Point 0.9555
1st Resistance Point 0.9217
Last Price 0.8880
1st Support Level 0.8621
2nd Support Level 0.8363
3rd Support Level 0.8025

See More

52-Week High 1.7200
Fibonacci 61.8% 1.2534
Fibonacci 50% 1.1093
Fibonacci 38.2% 0.9652
Last Price 0.8880
52-Week Low 0.4986

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar